Biden Targets Non-Compete Agreements, Which Restrict the Job Opportunities of Millions of Low-Wage Workers
Biden goes after non-compete agreements….but will this effort make a difference?
Read more...Category Archives: Regulations and regulators
Robinhood’s Revealing Ad Pitch: We’re All Investors, Alone
The latest Robinhood campaign is more raspberry than rah rah.
Read more...When Counterculture Goes Mainstream: A Dispatch from the 2021 Bitcoin Conference
How Bitcoin hard-core loyalists see the future of their project.
Read more...Industry Calls the Climate Shots in the Biden Administration
And you believed Biden on climate change?
Read more...Michael Hudson Discusses Financialization, Rentierism, and Other Favorite Topics with Jessi Ora of Swedish Positiva Pengar Group
Michael Hudson gives another wide-ranging, tour de force interview. Enjoy!
Read more...Steve Wozniak Endorses the Right to Repair
Last week, President Joe Biden and Apple co-founder Steve Wozniak endorsed the right to repair.
Read more...Understanding the Opioid Epidemic: When Innovation Fails, or Rather Works Too Well
The opioid crisis provides a deadly example of why innovation often is simply a new-fangled form of predation.
Read more...The Future of Alzheimer’s Pharmaceutical Aducanumab – as a Medicine and as a Financial Product – What Happens Now?
The more you look at aducanumab, both the dubious FDA approval and the thin odds that it will perform medically, the less there is to like.
Read more...War on Science Persists Within Biden EPA as Staffers Allege Chemical Reports Altered
Whistleblowers charge that Trump-style doctoring of scientific reports is continuing under Biden.
Read more...How Intel Financialized and Lost Leadership in Semiconductor Fabrication
Intel is the poster child of how stock buybacks come at the cost of technological innovation.
Read more...A Quick Comment on China Stomping on Chinese Stock Listings in the US
Another big and costly dustup over Chinese listings in the US. But now Chinese officials signal they want broad-scale change.
Read more...Aducanumab Approval, Part 2: Dirty Drug Dealings
Yves here. We’re doing a bit of catchup by featuring some significant stories that were still crowded out a bit due to the competing news plus the Fourth of July tuneout. One is on the super dodgy approval of the big ticket, very dubious effectiveness Alzheimer’s drug Aducanumab. And “big ticket” is no understatement; the […]
Read more...Democrats Prepare to Privatize Medicare, Using Medicare Advantage as Their Opening Wedge (and New York Unions?)
The Democrat plan to privatize Medicare by expanding the private, for-profit Medicare Advantage program
Read more...Biden Administration Issues Interim Rule Barring Surprise Billing
The health care grift knows as surprise billing is about to be largely stamped out.
Read more...Amazon Arrogance Backfires, Tries to Smear Incoming FTC Chair Lina Khan as Needing to Recuse Herself Because She Knows Them Too Well
Amazon looks to be having a meltdown over new FTC chief Lina Khan. Good.
Read more...